Highlights Veracyte, Inc.

Equities

VCYT

US92337F1075

Market Closed - Nasdaq Other stock markets 01:30:00 21/06/2024 am IST			5-day change	1st Jan Change
21.76 ^USD	+1.63%		-0.14%	-20.90%

03/06	Veracyte, Inc. Announces New Afirma Grid Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors	CI
07/05	Earnings Flash (VCYT) VERACYTE Posts Q1 Revenue $96.8M, vs. Street Est of $93.4M	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Veracyte, Inc. Announces New Afirma Grid Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors	04/06	CI
Earnings Flash (VCYT) VERACYTE Posts Q1 Revenue $96.8M, vs. Street Est of $93.4M	08/05	MT
Veracyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2024	08/05	CI
Earnings Flash (VCYT) VERACYTE Reports Q4 Revenue $98.2M, vs. Street Est of $92.8M	23/02	MT
Veracyte, Inc. Provides Earnings Guidance for the Full Year 2024	23/02	CI
Veracyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02	CI
Veracyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	23/02	CI
Veracyte Closes $70 Million C2i Genomics Acquisition	07/02	MT
Veracyte, Inc. completed the acquisition of C2i Genomics, Inc. for approximately $100 million.	05/02	CI
Veracyte, Inc. Provides Preliminary Unaudited Earnings Results for Fourth Quarter and Full Year Ended December 31, 2023	08/01	CI
Veracyte, Inc. has reached a definitive agreement to acquire C2i Genomics, Inc. for $95 million.	08/01	CI
Veracyte's Q3 Loss Widens, Revenue Increases; Raises 2023 Revenue Outlook	08/11	MT
Earnings Flash (VCYT) VERACYTE Reports Q3 Revenue $90.1M, vs. Street Est of $84.4M	08/11	MT
Veracyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11	CI
Veracyte, Inc. Raises Revenue Guidance for the Full Year 2023	08/11	CI
Veracyte, Inc. Announces New Data from A Large, Randomized Phase 3 Trial Reinforce the Value of the Decipher Prostate Genomic Classifier in Helping Physicians Make More Informed Treatment Decisions for Their Patients with Prostate Cancer	05/23/05	CI
Veracyte, Inc. Announces New Data Presented At the 2023 American Thyroid Association Annual Meeting Demonstrate That Veracyte's Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer	29/23/29	CI
Veracyte, Inc. and Gustave Roussy Announces Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies	06/23/06	CI
Veracyte, Inc. Announces Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer	22/23/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Veracyte, Inc.

Equities

VCYT

US92337F1075

Highlights

Filters